EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells

Miaomiao Chen, Wenjian Chen, Shiwen Sun, Yanli Lu, Guoxiu Wu, Hongyu Xu, Huiru Yang, Chong Li, Weizhi He, Mingyang Xu, Xiuhua Li, Dong Jiang und 4 weitere

Journal of Advanced Research · 2025

DOI: 10.1016/j.jare.2024.08.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Advanced Research, 2025. Verfasst von Miaomiao Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Science…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cellular Senescence, Pyridines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jiangxi Province, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Owing to the limited treatment options for hepatocellular carcinoma (HCC), interventions targeting pre-HCC stages have attracted increasing attention. In the pre-HCC stage, hepatic tumor-initiating cells (hTICs) proliferate abnormally and contribute to hepatocarcinogenesis. Numerous studies have investigated targeted senescence induction as an HCC intervention. However, it remains to be clarified whether senescence induction of hTICs could serve as a pre-HCC intervention. OBJECTIVES: This study was designed to investigate whether senescence induction of hTICs in the precancerous stage inhibit HCC initiation. METHODS AND RESULTS: HCC models developed from chronic liver injury (CLI) were established by using Fah-/- mice and N-Ras + AKT mice. PD-0332991, a selective CDK4/6 inhibitor that blocks the G1/S transition in proliferating cells, was used to induce senescence during the pre-HCC stage. Upon administration of PD-0332991, we observed a significant reduction in HCC incidence following selective senescence induction in hTICs, and an alleviation liver injury in the CLI-HCC models. PD-0332991 also induced senescence in vitro in cultured hTICs isolated from CLI-HCC models. Moreover, RNA sequencing (RNA-seq) analysis delineated that the "Cyclin D-CDK4/6-INK4-Rb" pathway was activated in both mouse and human liver samples during the pre-HCC stage, while PD-0332991 exhibited substantial inhibition of this pathway, thereby inducing cellular senescence in hTICs. Regarding the immune microenvironment, we demonstrated that senescent hTICs secrete key senescence-associated secretory phenotypic (SASP) factors, CXCL10 and CCL2, to activate and recruit macrophages, and contribute to immune surveillance. CONCLUSION: We found that hTICs can be targeted and induced into a senescent state during the pre-HCC stage. The SASP factors released by senescent hTICs further activate the immune response, facilitating the clearance of hTICs, and consequently suppressing HCC occurrence. We highlight the importance of pre-HCC interventions and propose that senescence-inducing drugs hold promise for preventing HCC initiation under CLI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cellular SenescencePyridinesLiver NeoplasmsCarcinoma, HepatocellularPiperazinesNeoplastic Stem CellsAnimalsMiceHumansDisease Models, AnimalCarcinogenesisMaleProtein Kinase InhibitorsCell Proliferation

Stichwörter der Autor:innen

CDK4/6 inhibitorsCellular senescenceCyclin D-CDK4/6-INK4-Rb pathwayHCCTumor-initiating cells

Substanzen

palbociclibCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6PyridinesPiperazinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200123, P. R. China; Sha…
  • Zhoupu Community Health Service Center of Pudong New Area, Shanghai, China.

Förderung

  • Natural Science Foundation of Jiangxi Province
  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • National Key Research and Development Program of China

Zitieren

APA

Chen, M., Chen, W., Sun, S., Lu, Y., Wu, G., Xu, H., Yang, H., Li, C., He, W., Xu, M., Li, X., Jiang, D., Cai, Y., Liu, C., Zhang, W., & He, Z. (2025). CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2024.08.034

Vancouver

Chen M, Chen W, Sun S, Lu Y, Wu G, Xu H, et al. CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells. Journal of Advanced Research. 2025. doi:10.1016/j.jare.2024.08.034

BibTeX
@article{Chen2025,
  author = {Chen, Miaomiao and Chen, Wenjian and Sun, Shiwen and Lu, Yanli and Wu, Guoxiu and Xu, Hongyu and Yang, Huiru and Li, Chong and He, Weizhi and Xu, Mingyang and Li, Xiuhua and Jiang, Dong and Cai, Yongchao and Liu, Changcheng and Zhang, Wencheng and He, Zhiying},
  title = {CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells},
  journal = {Journal of Advanced Research},
  year = {2025},
  doi = {10.1016/j.jare.2024.08.034}
}
Kostenlos starten →